An exploratory, open-label, single centre, phase II, proof of concept study of gevokizumab treatment in patients with Schnitzler syndrome.

Trial Profile

An exploratory, open-label, single centre, phase II, proof of concept study of gevokizumab treatment in patients with Schnitzler syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2016

At a glance

  • Drugs Gevokizumab (Primary)
  • Indications Schnitzler syndrome
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors ADIR; IRIS; Servier
  • Most Recent Events

    • 02 Mar 2016 Status changed from recruiting to completed, according to European Clinical Trials Database record.
    • 12 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top